日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

XPO1 inhibition in KRAS-mutant cancers: time for clinical trials but how?

KRAS突变型癌症中的XPO1抑制:是时候进行临床试验了,但该如何进行?

Nagasaka, Misako; Khan, Husain Y; Luo, Faustine; Al-Hallak, Mohammed Najeeb; Saif, Muhammad Wasif; Mohammad, Ramzi M; Azmi, Asfar S

PCNA Inhibition Enhances the Antitumor Activity of KRAS-Targeted Therapies in Pancreatic Cancer

PCNA抑制增强KRAS靶向疗法在胰腺癌中的抗肿瘤活性

Bannoura, Sahar F; Khan, Husain Yar; Aboukameel, Amro; Wan, Yin; Bao, Bin; Uddin, Md Hafiz; Jimenez, Hugo; Aboukameel, Adeeb; Siddiqui, Rayyan; Khan, Filza; Haratipour, Pouya; Gu, Long; Beydoun, Rafic; Saif, Muhammad Wasif; Tobon, Miguel; Philip, Philip A; El-Rayes, Bassel; Chen, Herbert; Hickey, Robert J; Malkas, Linda; Shi, Yang; Al Hallak, Mohammed Najeeb; Mohammad, Ramzi M; Pasche, Boris C; Azmi, Asfar S

Co-targeting KRAS and Exportin1 as an effective therapeutic strategy for KRASG12D mutant pancreatic ductal adenocarcinoma

联合靶向KRAS和Exportin1是治疗KRASG12D突变型胰腺导管腺癌的有效策略

Khan, Husain Yar; Al Hallak, Mohammed Najeeb; Aboukameel, Amro; Bannoura, Sahar F; Uddin, Md Hafiz; Aboukameel, Adeeb A; Alkan, Fulya Koksalar; Caglayan, Ahmet B; Alkan, Hilmi K; Bao, Bin; Jimenez, Hugo; Johansen, Allan M; McGrath, Callum; Barker, Grayson; Choucair, Khalil; Tubon, Miguel; Beal, Eliza; Kim, Steve; Beydoun, Rafic; Dyson, Gregory; Shi, Yang; Nagasaka, Misako; Atfi, Azeddine; Korkaya, Hasan; Saif, Muhammad Wasif; Philip, Philip A; El-Rayes, Bassel; Chen, Herbert; Shields, Anthony F; Mohammad, Ramzi M; Pasche, Boris C; Azmi, Asfar S

Multiomic Characterization of RCC1 and RCC2 Expression and Their Association With Molecular Alterations, Immune Phenotypes, and Cancer Outcomes

RCC1和RCC2表达的多组学特征及其与分子改变、免疫表型和癌症预后的关系

Nagasaka, Misako; Warnecke, Brian; Ou, Sai-Hong Ignatius; Bannoura, Sahar F; Kim, Chul; Elliott, Andrew; Halmos, Balazs; Hoon, Dave; Darabi, Sourat; Sukari, Ammar; Radovich, Milan; Lou, Emil; Sledge, George; El-Deiry, Wafik; Al-Hallak, Mohammed Najeeb; Pasche, Boris C; Azmi, Asfar S

RCC1 regulation of subcellular protein localization via Ran GTPase drives pancreatic ductal adenocarcinoma growth.

RCC1 通过 Ran GTPase 调控亚细胞蛋白定位,从而驱动胰腺导管腺癌的生长

Bannoura Sahar F, Aboukameel Amro, Khan Husain Yar, Uddin Md Hafiz, Jang Hyejeong, Beal Eliza W, Thangasamy Amalraj, Shi Yang, Kim Seongho, Wagner Kay-Uwe, Beydoun Rafic, El-Rayes Bassel F, Philip Philip A, Mohammad Ramzi M, Saif Muhammad Wasif, Al-Hallak Mohammed Najeeb, Pasche Boris C, Azmi Asfar S

The phase I/II eNRGy trial: Zenocutuzumab in patients with cancers harboring NRG1 gene fusions

I/II期eNRGy试验:Zenocutuzumab治疗携带NRG1基因融合的癌症患者

Kim, Dong-Wan; Schram, Alison M; Hollebecque, Antoine; Nishino, Kazumi; Macarulla, Teresa; Rha, Sun Young; Duruisseaux, Michaël; Liu, Stephen V; Al Hallak, Mohammed Najeeb; Umemoto, Kumiko; Wesseler, Claas; Cleary, James M; Springfeld, Christoph; Neuzillet, Cindy; Joe, Andrew; Jauhari, Shekeab; Ford, Jim; Goto, Koichi

Association between cannabis use and clinical outcomes in patients with solid malignancies receiving immune checkpoint inhibitors

大麻使用与接受免疫检查点抑制剂治疗的实体恶性肿瘤患者的临床结果之间的关联

Hadid, Tarik; Biedny, Adam; Mamdani, Hirva; Azmi, Asfar; Kim, Seongho; Jang, Hyejeong; Uprety, Dipesh; Al Hallak, Mohammed Najeeb; Sukari, Ammar

Pan-tumor survey of RET fusions as detected by next-generation RNA sequencing identified RET fusion positive colorectal carcinoma as a unique molecular subset

利用新一代RNA测序技术对RET融合基因进行全肿瘤筛查,发现RET融合阳性的结直肠癌是一个独特的分子亚群。

Nagasaka, Misako; Brazel, Danielle; Baca, Yasmine; Xiu, Joanne; Al-Hallak, Mohammed Najeeb; Kim, Chul; Nieva, Jorge; Swensen, Jeffrey J; Spetzler, David; Korn, Wolfgang Michael; Socinski, Mark A; Raez, Luis E; Halmos, Balazs; Ou, Sai-Hong Ignatius

Primary Squamous Cell Biliary Carcinoma With Liver Metastasis Is Rare but Malicious

原发性胆道鳞状细胞癌伴肝转移虽然罕见,但危害极大

Almujarkesh, Mohamad Khaled; Damughatla, Anirudh R; Bathla, Jasdeep; Sugg, Kyle; LaBuda, Dana; Alkassis, Samer; Al Hallak, Mohammed Najeeb

Anticancer efficacy of KRASG12C inhibitors is potentiated by PAK4 inhibitor KPT9274 in preclinical models of KRASG12C mutant pancreatic and lung cancers

在KRASG12C突变型胰腺癌和肺癌的临床前模型中,PAK4抑制剂KPT9274可增强KRASG12C抑制剂的抗癌疗效。

Khan, Husain Yar; Nagasaka, Misako; Aboukameel, Amro; Alkhalili, Osama; Uddin, Md Hafiz; Bannoura, Sahar; Mzannar, Yousef; Azar, Ibrahim; Beal, Eliza; Tobon, Miguel; Kim, Steve; Beydoun, Rafic; Baloglu, Erkan; Senapedis, William; El-Rayes, Bassel; Philip, Philip A; Mohammad, Ramzi M; Shields, Anthony F; Al-Hallak, Mohammed Najeeb; Azmi, Asfar S